- Home
- PDD vs BMY Comparison
PDD vs BMY Comparison
Compare PDD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | BMY |
|---|---|---|
| Founded | 2015 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | 32500 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5B | 113.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDD | BMY |
|---|---|---|
| Price | $83.78 | $57.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $139.22 | $61.73 |
| AVG Volume (30 Days) | 7.5M | ★ 11.5M |
| Earning Date | 05-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.35 | N/A |
| Revenue Next Year | $12.63 | N/A |
| P/E Ratio | ★ $10.63 | $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.94 | $42.52 |
| 52 Week High | $139.41 | $62.89 |
Technical Indicators
Market Signals| Indicator | PDD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 49.67 |
| Support Level | $81.56 | $56.36 |
| Resistance Level | $107.53 | $57.91 |
| Average True Range (ATR) | 2.54 | 1.49 |
| MACD | 1.19 | 0.16 |
| Stochastic Oscillator | 76.49 | 46.84 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.